Theraxyte

About Theraxyte

Based in Beijing, China, Theraxyte BioScience is a biotechnology firm established in 2019 by Tong Zhao, who also serves as the company's CEO. The company operates within the drug discovery and delivery sector, concentrating on the development of therapeutics based on extracellular vesicles (EVs). Theraxyte secured $10 million in a seed funding round on July 11, 2022, with participation from investors including Novo and NHH Ventures.

The core of Theraxyte's operations is its proprietary TAXY® platform, an EV-based drug delivery system. This technology is engineered to facilitate the large-scale, GMP-level manufacturing of modifiable EVs. The platform focuses on effectively packaging therapeutic payloads, such as polypeptides and nucleic acids, and delivering them to specific organs or cells where the active molecules can be released. The company's business model appears to be centered on leveraging its platform technology for research and development, potentially through partnerships or licensing agreements with other biopharmaceutical companies. This approach allows partners to utilize Theraxyte's delivery system to develop and commercialize pharmaceutical products.

Theraxyte's EV-based therapeutics present several potential advantages over traditional therapies. These include a natural biological origin that may result in lower immunogenicity, the capacity to access difficult-to-reach areas of the body like crossing the blood-brain barrier, and a flexible, modifiable composition. The company is actively building its intellectual property portfolio, with at least one pending patent for compositions and methods related to culturing stem cells. By advancing its TAXY® platform, Theraxyte aims to address significant challenges in therapeutic applications and contribute to human health by developing novel treatments.